Press Release: AesthetiCare, a division of Ferndale Pharmaceuticals Ltd and Aesthetic Technology Ltd Strengthen Collaboration
Ferndale Pharmaceuticals Ltd, a speciality dermatology company, and Aesthetic Technology Ltd, the developers and manufacturers of Dermalux LED phototherapy systems, are pleased to announce they have strengthened their collaboration, with Ferndale Pharmaceuticals acquiring 30% of the Aesthetic Technology shares.
This strengthens the commercial joint venture between the two companies with the Ferndale Pharmaceuticals aesthetic division, AesthetiCare, integrating Dermalux into it’s aesthetic skin system portfolio, and Aesthetic Technology accelerating it’s expansion in the professional beauty and spa sectors. The combined teams will work closely together to provide the highest levels of clinical and business support to our existing and new customers.
The new corporate joint venture will utilise the enhanced financial strength and operational infrastructures Ferndale can provide, supporting the exciting growth of Dermalux and its already developing international presence. The wider experience of the Ferndale Pharma Group Inc. USA will also prove a valuable resource with the latter.
With an exciting pipeline of dermatological product and business development opportunities the future for the two companies and their collective customers is bright.
Roger Bloxham, Managing Director of Ferndale Pharmaceuticals Ltd and AesthetiCare said: “We are delighted to have invested in Aesthetic Technology Ltd; such an exciting and innovative company that have already made a great impact in the UK aesthetic market, and have excellent international expansion and product development opportunities. They are fantastic people to work with, we share the same goals of evidence-based treatments providing natural, great looking skin and long lasting results, and look forward to delivering these to skin clinics together in a strengthened collaboration.”
Huw Anthony, Managing Director of Aesthetic Technology Ltd said: “Having enjoyed working closely over the past 12 months, the opportunity to join forces on a formal commercial basis with AesthetiCare was far too good to miss, and we are proud to welcome them as shareholders in the business. In addition to the obvious appeal in the UK, to be able to work alongside Ferndale Pharma Group Inc. USA on an international basis is a fantastic development and one that strengthens the Dermalux brand in every respect. We have become great friends with Roger, Roisin and the team at AesthetiCare and look forward with anticipation and excitement as to what the future holds as we work together to develop existing and new Dermalux systems.”
For further information please contact:
Jenna Swift, Marketing Manager – AesthetiCare.
Phone: 01937 541122 Email: firstname.lastname@example.org
AesthetiCare is a trademark of Ferndale Pharmaceuticals Ltd
Dermalux is a trademark of Aesthetic Technology Ltd